SEASTAR MEDICAL HOLDING CORP (ICU) Fundamental Analysis & Valuation

NASDAQ:ICU • US81256L3024

2.58 USD
+0.07 (+2.79%)
Last: Mar 5, 2026, 08:00 PM

This ICU fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ICU. ICU was compared to 184 industry peers in the Health Care Equipment & Supplies industry. While ICU seems to be doing ok healthwise, there are quite some concerns on its profitability. ICU is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. ICU Profitability Analysis

1.1 Basic Checks

  • In the past year ICU has reported negative net income.
  • ICU had a negative operating cash flow in the past year.
  • In the past 5 years ICU always reported negative net income.
  • ICU had a negative operating cash flow in each of the past 5 years.
ICU Yearly Net Income VS EBIT VS OCF VS FCFICU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

  • ICU has a worse Return On Assets (-87.99%) than 76.63% of its industry peers.
  • ICU's Return On Equity of -119.20% is on the low side compared to the rest of the industry. ICU is outperformed by 64.67% of its industry peers.
Industry RankSector Rank
ROA -87.99%
ROE -119.2%
ROIC N/A
ROA(3y)-587.39%
ROA(5y)-528.31%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ICU Yearly ROA, ROE, ROICICU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 500 -500 1K 1.5K

1.3 Margins

  • ICU has a better Gross Margin (95.35%) than 99.46% of its industry peers.
  • The Profit Margin and Operating Margin are not available for ICU so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 95.35%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ICU Yearly Profit, Operating, Gross MarginsICU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -5K -10K -15K

6

2. ICU Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for ICU has been increased compared to 1 year ago.
  • The debt/assets ratio for ICU has been reduced compared to a year ago.
ICU Yearly Shares OutstandingICU Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 100K 200K 300K 400K 500K
ICU Yearly Total Debt VS Total AssetsICU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2M 4M 6M 8M

2.2 Solvency

  • ICU has an Altman-Z score of -14.11. This is a bad value and indicates that ICU is not financially healthy and even has some risk of bankruptcy.
  • ICU has a worse Altman-Z score (-14.11) than 83.15% of its industry peers.
  • There is no outstanding debt for ICU. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -14.11
ROIC/WACCN/A
WACCN/A
ICU Yearly LT Debt VS Equity VS FCFICU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 5M -5M -10M -15M

2.3 Liquidity

  • A Current Ratio of 3.66 indicates that ICU has no problem at all paying its short term obligations.
  • The Current ratio of ICU (3.66) is better than 63.04% of its industry peers.
  • ICU has a Quick Ratio of 3.64. This indicates that ICU is financially healthy and has no problem in meeting its short term obligations.
  • ICU has a Quick ratio of 3.64. This is in the better half of the industry: ICU outperforms 71.74% of its industry peers.
Industry RankSector Rank
Current Ratio 3.66
Quick Ratio 3.64
ICU Yearly Current Assets VS Current LiabilitesICU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

4

3. ICU Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 32.15% over the past year.
  • The Revenue has grown by 1195.59% in the past year. This is a very strong growth!
EPS 1Y (TTM)32.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-18.18%
Revenue 1Y (TTM)1195.59%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%169.12%

3.2 Future

  • Based on estimates for the next years, ICU will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.65% on average per year.
  • The Revenue is expected to grow by 147.47% on average over the next years. This is a very strong growth
EPS Next Y17.17%
EPS Next 2Y25.13%
EPS Next 3Y18.65%
EPS Next 5YN/A
Revenue Next Year601.24%
Revenue Next 2Y229.67%
Revenue Next 3Y147.47%
Revenue Next 5YN/A

3.3 Evolution

ICU Yearly Revenue VS EstimatesICU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 1M 2M 3M
ICU Yearly EPS VS EstimatesICU Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 -50 -100 -150 -200 -250

0

4. ICU Valuation Analysis

4.1 Price/Earnings Ratio

  • ICU reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year ICU is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ICU Price Earnings VS Forward Price EarningsICU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ICU Per share dataICU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6 -8

4.3 Compensation for Growth

  • ICU's earnings are expected to grow with 18.65% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.13%
EPS Next 3Y18.65%

0

5. ICU Dividend Analysis

5.1 Amount

  • No dividends for ICU!.
Industry RankSector Rank
Dividend Yield 0%

ICU Fundamentals: All Metrics, Ratios and Statistics

SEASTAR MEDICAL HOLDING CORP

NASDAQ:ICU (3/5/2026, 8:00:02 PM)

2.58

+0.07 (+2.79%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-13
Earnings (Next)03-25
Inst Owners3.03%
Inst Owner Change-27.08%
Ins Owners0.75%
Ins Owner Change0.65%
Market Cap9.29M
Revenue(TTM)881.00K
Net Income(TTM)-13.66M
Analysts80
Price Target9.18 (255.81%)
Short Float %8%
Short Ratio0.75
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)36.37%
Min EPS beat(2)14.19%
Max EPS beat(2)58.55%
EPS beat(4)3
Avg EPS beat(4)22.21%
Min EPS beat(4)-0.12%
Max EPS beat(4)58.55%
EPS beat(8)5
Avg EPS beat(8)3.4%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)19.9%
Min Revenue beat(2)-27.52%
Max Revenue beat(2)67.33%
Revenue beat(4)2
Avg Revenue beat(4)19.36%
Min Revenue beat(4)-55.78%
Max Revenue beat(4)93.4%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-10%
PT rev (3m)800%
EPS NQ rev (1m)-2.42%
EPS NQ rev (3m)-715.38%
EPS NY rev (1m)-4.16%
EPS NY rev (3m)-786.11%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)52.04%
Revenue NY rev (1m)0%
Revenue NY rev (3m)24.32%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.54
P/FCF N/A
P/OCF N/A
P/B 0.81
P/tB 0.81
EV/EBITDA N/A
EPS(TTM)-8.4
EYN/A
EPS(NY)-3.38
Fwd EYN/A
FCF(TTM)-3.94
FCFYN/A
OCF(TTM)-3.94
OCFYN/A
SpS0.24
BVpS3.18
TBVpS3.18
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -87.99%
ROE -119.2%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 95.35%
FCFM N/A
ROA(3y)-587.39%
ROA(5y)-528.31%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.66
Quick Ratio 3.64
Altman-Z -14.11
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-18.18%
EPS Next Y17.17%
EPS Next 2Y25.13%
EPS Next 3Y18.65%
EPS Next 5YN/A
Revenue 1Y (TTM)1195.59%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%169.12%
Revenue Next Year601.24%
Revenue Next 2Y229.67%
Revenue Next 3Y147.47%
Revenue Next 5YN/A
EBIT growth 1Y13.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-27.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-27.91%
OCF growth 3YN/A
OCF growth 5YN/A

SEASTAR MEDICAL HOLDING CORP / ICU FAQ

Can you provide the ChartMill fundamental rating for SEASTAR MEDICAL HOLDING CORP?

ChartMill assigns a fundamental rating of 3 / 10 to ICU.


What is the valuation status for ICU stock?

ChartMill assigns a valuation rating of 0 / 10 to SEASTAR MEDICAL HOLDING CORP (ICU). This can be considered as Overvalued.


What is the profitability of ICU stock?

SEASTAR MEDICAL HOLDING CORP (ICU) has a profitability rating of 1 / 10.


What is the expected EPS growth for SEASTAR MEDICAL HOLDING CORP (ICU) stock?

The Earnings per Share (EPS) of SEASTAR MEDICAL HOLDING CORP (ICU) is expected to grow by 17.17% in the next year.